Back
$BPMC filed their 14D9 with the SEC today that includes, among other things, a copy of the financial forecast that included revenue projections provided $SNY Attached is a worksheet that compares the forecasts provided by BPMC to analyst consensus revenue estimates per Seeking Alpha & Fintel. It is interesting to note that analyst consensus revenue estimates are dramatically lower that what BPMC provided. It has been our experience that differences between the 2 are historically minor. If anything, it is our experience analysts are higher than management (esp. MRTX). We had noted that SNY was buying BPMC for $9.1B which was 0.51X 10-year projected revenues. Using BPMC prepared forecasts, SNY is buying BPMC for 0.37X 10 year revenue estimates. There is no other point or objective of this post. This is not investment advice. $XBI
1
3

Since Post

Full Details
@Night_Owl_Biotech It's interesting, thanks for the post and comparison I believe there are two factors at play 1) analyst numbers drop off after a few years (as shown in your top left table) which means the latter years of the analyst estimates are based on fewer analysts and less reliable 2) in general, the quality of analyst forecasts can be VERY hit and miss even on a good day. I have notice this with companies I follow. Huge revisions and nonsensical revisions are common. I get the impression they're made to follow a large number of companies and can't research them properly, unless it's a high profile company or something
1